CROBM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rowe, P. S.N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rowe, P. S.N.

THE WRICKKENED PATHWAYS OF FGF23, MEPE AND PHEX

Peter S.N. Rowe

Department of Periodontics, The University of Texas Health Science Center at San Antonio, Mail Code 7894, 7703 Floyd Curl Drive, Room 3.579U, San Antonio, TX 78229-3900, USA; rowep{at}uthscsa.edu



View larger version (16K):

[in a new window]
 
Figure 1. Proposed role for PHEX, MEPE, and the ASARM peptide in mineralization. MEPE and osteoblastic proteases (NEP, ECEL-1/DINE, and cathepsin-D) are markedly up-regulated in murine hyp-osteoblasts that have defective phex (Jo et al., 2000, 2001; Argiro et al., 2001; Bai et al., 2002; Dubois et al., 2002; Guo et al., 2002; Liu et al., 2003). PHEX/phex protects MEPE from cathepsin-B and general protease degradation and prevents release of the ASARM peptide (Guo et al., 2002). Cathepsin-B is also expressed in the osteoblast (Aisa et al., 1996, 2003). Thus, in HYP/hyp, elevated MEPE (with elevated osteoblastic proteases and loss of PHEX protease protection of MEPE) results in elevated levels of protease-resistant MEPE-ASARM peptide. The MEPE-ASARM peptide inhibits mineralization in vivo, and the osteopontin ASARM peptide potently inhibits calcium oxalate crystallization and crystal growth (Rowe et al., 2000, 2004; Hoyer et al., 2001). Also, the salivary statherin ASARM peptide (see Fig. 2Go) plays a direct biological role in inhibiting spontaneous precipitation of supersaturated salivary calcium and phosphate and maintaining the mineralization dynamics of tooth enamel (Schlesinger and Hay, 1977; Bennick et al., 1981; Raj et al., 1992; Long et al., 1998). Of related interest, the MEPE knockout, as expected, has accelerated mineralization and increased bone density and bone formation (Gowen et al., 2003). Mineral maturity (mineral crystal size and perfection) throughout all anatomic regions of the osteopontin knock-out mouse bone are also significantly increased (Boskey et al., 2002).

 


View larger version (29K):

[in a new window]
 
Figure 2. Salivary-statherin & MEPE consensus ASARM motif: mineralization-inhibition and ancestral genes on chromosome 4. MEPE, DMP-1, and the SIBLINGs are related to an ancestral mineralization-gene (salivary statherin) that is also thought to function in the transport of calcium and phosphate in salivary glands. Statherin maps to chromosome 4 in the SIBLING/MEPE region and also contains an ASARM motif. (A) A clustal alignment of the COOH terminal region of human-DMP-1, human-MEPE, mouse-MEPE, and rat-MEPE with human-statherin (62-residue protein). In MEPE and DMP-1, the ASARM peptide occupies the most distal COOH-region of the molecule and is highlighted with a boxed cartouche labeled ‘MEPE ASARM peptide’. The boxed cartouche labeled as ‘statherin-ASARM peptide’ contains the sequence shown to play a biological role in inhibiting spontaneous precipitation of supersaturated salivary calcium and phosphate and maintaining the mineralization dynamics of tooth enamel (Schlesinger and Hay, 1977; Bennick et al., 1981; Raj et al., 1992; Long et al., 1998). Statherin is also thought to function in the transport of calcium and phosphate in salivary glands (Raj et al., 1992). In both MEPE and statherin, cathepsin-B and/or general protease cleavage results in the release of MEPE and statherin protease-resistant ASARM peptides. Both MEPE and statherin ASARM peptides are phosphorylated, protease-resistant, acidic and highly charged molecules with low pI’s. They also share biological properties. For example, a feature of the MEPE ASARM region is the repeat (D) SSES/E sequence. This short sequence has been shown to be a key inhibitor of hydroxyapatite crystal formation and mineralization in salivary statherin (Raj et al., 1992; Long et al., 1998). (B) Schematic presentation of the remarkable clustering of MEPE, DMP-1, statherin, and other SIBLING genes on chromosome 4.

 


View larger version (43K):

[in a new window]
 
Figure 3. Normal physiology. A scheme representing the proposed dynamic and interactive roles of PHEX, FGF23, MEPE, and matrix proteins in maintaining normal tooth-bone-renal-mineralization and phosphate homeostasis. See text for detailed description (specifically, the subparagraph entitled ‘Normal Physiology [Global Hypothesis]’). Also refer to the TableGo for more details concerning the icons used to represent the diverse molecules, pathways, and tissues.

 


View larger version (46K):

[in a new window]
 
Figure 4. X-linked rickets (Hyp). A cartoon illustrating the proposed changes in X-linked hypophosphatemic rickets. The primary defect in this disease is the PHEX gene, and this has an impact on renal phosphate handling, vitamin D metabolism, and mineralization. For comparison with normal states, see Fig. 3Go. See text for detailed description (specifically, the subparagraph entitled ‘X-linked hypophosphatemic rickets [Hyp] [Global Hypothesis]’). Also refer to the TableGo for more details concerning the icons used to represent the diverse molecules, pathways, and tissues.

 


View larger version (43K):

[in a new window]
 
Figure 5. Autosomal-dominant hypophosphatemic rickets (ADHR). Global scheme proposing the changes in autosomal-dominant hypophosphatemic rickets (ADHR). See text for detailed description (specifically, the subparagraph entitled ‘Autosomal-dominant hypophosphatemic rickets [ADHR] [Global Hypothesis]’). Also refer to the TableGo for more details concerning the icons used to represent the diverse molecules, pathways, and tissues.

 


View larger version (49K):

[in a new window]
 
Figure 6. Oncogenic hypophosphatemic hypophosphatemia (OHO). Global scheme proposing the changes in oncogenic hypophosphatemic osteomalacia, also known as tumor-induced osteomalacia (OHO). See text for detailed description (specifically, the subparagraph entitled ‘Tumor-induced osteomalacia [OHO] [Global Hypothesis]’). Also refer to the TableGo for more details concerning the icons used to represent the diverse molecules, pathways, and tissues.

 


View larger version (44K):

[in a new window]
 
Figure 7. The phex transgenic hyp-mouse: hyp-mice with re-introduced wild-type phex genes have partially corrected mineralization phenotypes and remain hypophosphatemic. See text for a full explanation of the proposed model for the experimental observations (specifically, the subparagraph entitled ‘HYP-PHEX transgenic [partial correction of mineralization phenotype] [Global Hypothesis]’). Also refer to the TableGo for more details concerning the icons used to represent the diverse molecules, pathways, and tissues.

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
IADR Journals Advances in Dental Research ®
Journal of Dental Research ® Critical Reviews (1990-2004)
Copyright © 2004 Institutional Access Guidelines